Efficacy Of Erlotinib And Gefitinib On Advanced Non-small Cell Lung Cancer And Analysis Of Survival Associated Factors

[Objective] To evaluate the efficacy and safety of Erlotinib and Gefitinib on the median overall survival time, median progression free survival time, response rate,disease control rate of the patients with advanced non-small cell lung cancer (NSCLC) and to identify the survival associated factors.[Methods] From March 2005 to August 2008,301 consecutive patients with advanced NSCLC in our hospital, who received gefitinib or erlotinib, were reviewed. EGFR mutation was analyzed by DNA sequencing in some cases. Efficacy and overall survival were analyzed by CHISS software.[Results] The overall response rate and disease control rate were 9.89%and 73.16%.One and two year survival rate were 60%and 28%respectively. The median progress free survival time and the median overall survival time of all patients were 6.44 months was 15.55 months. Patients who were never smoker and adenocarcinoma(including bronchioalveolar carcinoma) showed better response than the opposite population. Patients who had adenocarcinoma (including bronchioalveolar carcinoma) and those who had operation before had significantly longer median survival time. The pathology,operation status,response to gefitinib/erlotinib were independent prognostic factors of median survival time and overall survival time of erlotinib/gefitinib treatment by Cox proportional hazard models. Gender, histology and other status had no significant effects on the clinical outcome and long-term survival time. Analyze of patients who were never smoker,or adenocarcinoma (including bronchioalveolar carcinoma), or squamous carcinoma,or smoker, showed that Gefitinib was effective in NSCLC as well as Erlotinib. Gefitinib and Erlotinib were well tolerant, with rash and diarrhea as commonly adverse events.[Conclusion] Gefitinib as well as Erlotinib had good efficacy to the patients with advanced or metastasis NSCLC in China. Adenocarcinoma (including bronchioalveolar carcinoma),being have operation before, response and disease control were prognostic factors in advanced NSCLC.